Currently, the disease-modifying therapies (DMTs) market for Alzheimer’s disease (AD) is in its early stage of development, as the first DMT for AD (lecanemab) was granted full approval by the U.S. FDA in July 2023. Several DMTs are in late-stage (phase 2 and above) clinical trials. If approved, they can expand the AD DMTs market significantly. The publisher estimates market data for 2024 (the base year) and forecasts values for 2025 through 2030. Other than the approved products, the revenue forecast also considers the potential therapeutic candidates expected to enter during the forecast period and their targeted market potential.
The report analyzes the AD DMTs market by target type (anti-amyloid and other emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, the Middle East, and Africa).
Report Includes
The report analyzes the AD DMTs market by target type (anti-amyloid and other emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, the Middle East, and Africa).
Report Includes
- Analysis of the current and future global market for disease-modifying therapies for Alzheimer’s disease (AD)
- Analyses of the global market trends, with market revenue data (sales figures) from 2023 to 2025, forecasts for 2026, and projected CAGRs through 2030
- Estimates of the market’s size and revenue prospects for the global market, accompanied by a market share analysis based on target type, drug type, drug molecule type, and region
- Facts and figures pertaining to market dynamics, technological advancements, regulations, prospects, and the impacts of macroeconomic variables
- Discussion of the underlying opportunities and potential in the disease-modifying therapies market
- Information on products currently available for the diagnosis and treatment of Alzheimer’s, as well as the promising new drug candidates and diagnostic imaging agents
- Review of key marketed products, clinical trials, competitive scenario and R&D activities
- An analysis of emerging trends and the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of the leading companies
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Market Segment Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Appendix
List of Tables
List of Figures
Executive Summary
This report provides an overview of the global and regional markets for disease-modifying therapies for Alzheimer’s disease. It includes global revenue ($ million) for base year data of 2024, estimates for 2025, and CAGR forecasts through 2030.Currently, the disease-modifying therapies (DMTs) market for Alzheimer’s disease (AD) is in its early stage of development, as the first DMT for AD (lecanemab) was granted full approval by the U.S. FDA in July 2023. Several DMTs are in late-stage (phase 2 and above) clinical trials. If approved, they can expand the AD DMTs market significantly. The publisher estimates market data for 2024 (the base year) and forecasts values for 2025 through 2030. Other than the approved products, the revenue forecast also considers the potential therapeutic candidates expected to enter during the forecast period and their targeted market potential.
Companies Mentioned
- Alzheon Inc.
- Anavex Life Sciences Corp.
- Annovis Bio Inc.
- Biogen
- Biovie Inc.
- Eisai Co. Ltd.
- Johnson & Johnson Services Inc.
- Lilly
- Novo Nordisk A/S
- Taurx Pharmaceuticals Ltd.
